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Summary
Background: Different approaches for an effective quality management
are funded by the Ministry of Health to verify, to assess and, if necessary,
to optimize the quality of health care using the tracer diagnoses of breast,
rectal, and lung cancer in eight regions in Germany.The conception of these
observational studies and initial findings are shown here, using breast
cancer in the region of Munich (population 2.4 million) as an example.
Patients and Methods: The study started on April 1, 1996. The recruitment
phase for all primary breast cancer patients in this region is planned for 
2 years with a 3–5-year follow-up. Established documentation sheets are
used to document basic medical information of each patient, along with
the original reports (pathology, radiotherapy, doctors’ reports, etc.),
follow-up reports and quality of life questionnaires (QLQ, including the
EORTC QLQ C30). Results: In 1996, the Munich region has a crude inci-
dence of 125/100,000 women (world standard 71.5). After almost complete
documentation the incidence is 10–15% higher. In the period from April 1,
1996 to June 30, 1997 1,360 patients have been recruited into the study.
79% of the patients were 50 years of age or older. pT stages are distributed
as follows: pTIS 5%, pT1 54%, pT2 32%, pT3 4%, pT4 6%. 4.5% had
primary metastases. Breast-conserving therapy (BCT) was performed in
57% of patients. Five of the 46 departments involved recruited more than
50 patients each within these 14 months. These larger departments treat
59% of all patients. The proportion of older patients and pT4 stages is
significantly higher in the smaller departments. BCT is performed signifi-
cantly more often in the larger departments. First results of quality of life
show dependencies on age, but no differences between mastectomy and
BCT 3 months after operation. Not only the addressed patients (response
rate to QLQ over 80%) but also almost all hospitals and many physicians
are willing to support and to partake in quality assurance. 35 hospitals, 
46 surgical departments, 80 heads of department and surgically active
general practioners, 330 general practioners, 7 radiotherapy departments,
and 13 pathology departments have so far documented for this study.
Conclusions: An effective quality management in oncology needs a modern
cancer registry which uses documentation sheets as well as original reports
and organizes the complicated infrastructure for an interdisciplinary
cooperation. To be able to evaluate the health care reality, it is necessary
to carry out a data analysis and assess each individual case. A feedback of
the results have to be available for each physician and each department.
The cost of this information management is approximately 0.3% of the
health care cost for this group of patients.
Schlüsselwörter
Qualitätsmanagement · Mammakarzinom · Bevölkerungsbezogen · 
Tumorregister · Lebensqualität
Zusammenfassung
Hintergrund: Als Modellprogramm für ein effektives Qualitätsmanage-
ment werden anhand der Tracerdiagnosen Mamma-, Rektum- und Lungen-
karzinom in 8 Regionen Deutschlands sogenannten Feldstudien vom
Bundesministerium für Gesundheit (BMG) gefördert, um die Qualität der
Versorgung zu belegen, zu bewerten und gegebenenfalls zu optimieren.
Für die Region München (2,4 Mill. Einwohner) werden die Konzeption
und erste Ergebnisse einer solchen Beobachtungsstudie zum Mamma-
karzinom vorgestellt. Patienten und Methoden: Beginn der Studie war der
1. April 1996. Flächendeckend sollen zunächst innerhalb von 2 Jahren alle
Neuerkrankungen an Brustkrebs in dieser Region erfaßt und 3–5 Jahre
nachbeobachtet werden. Als Erfassungsinstrumente dienen etablierte
Erhebungsbögen zu den medizinischen Basisdaten, Originalberichte
(Pathologiebefunde, Arztbriefe usw.), Folgeerhebungsbögen und Lebens-
qualitätsfragebögen, welche auch den Fragebogen der EORTC (QLQ
C30) beinhalten. Ergebnisse: Für das Jahr 1996 wurde für das Stadtgebiet
München eine rohe Inzidenz von 125/100 000 Frauen (Weltstandard 71,5)
ermittelt. Nach vollständiger Erfassung werden die Inzidenzen noch
10–15% höher liegen. Vom 1. April 1996 bis zum 30. Juni 1997 wurden
1360 Patientinnen rekrutiert. 79% der Patientinnen waren 50 Jahre und
älter. Die pT-Stadien waren wie folgt verteilt: pTIS 5%, pT1 54%, pT2 32%,
pT3 4%, pT4 6%. Primär metastasiert waren 4,5%. Eine brusterhaltende
Therapie (BET) wurde in 57% der Fälle durchgeführt. In den 14 Monaten
rekrutierten 5 der insgesamt 46 beteiligten Abteilungen jeweils mehr als
50 Patientinnen. In diesen größeren Abteilungen werden 59% aller Patien-
tinnen versorgt. Der Anteil der älteren Patientinnen über 70 Jahre und der
pT4-Stadien ist in den kleineren Kliniken signifikant höher. Eine BET
wird in den größeren Kliniken signifikant öfter durchgeführt. Erste Ergeb-
nisse zur Lebensqualität zeigen 3 Monate nach Operation Abhängigkeiten
vom Alter, aber keine Unterschiede zwischen Mastektomie und BET.
Neben den angeschriebenen Patientinnen (Rückfallquote über 80%) sind
fast alle Krankenhäuser und viele Ärzte bereit, Qualitätssicherung zu
unterstützen. 35 Krankenhäuser, 46 operative Abteilungen, 80 Klinik- und
Abteilungsleiter und operativ tätige Belegärzte, 330 niedergelassene
Ärzte, 7 Strahlentherapie- und 13 Pathologie-Abteilungen haben bisher
Dokumentationsbeiträge geliefert. Schlußfolgerungen: Effektives Quali-
tätsmanagement in der Onkologie erfordert ein modernes Krebsregister
mit einer Dokumentation über Erhebungsbögen sowie Originaldoku-
mente, das die komplizierte Infrastruktur für eine interdisziplinäre Zu-
sammenarbeit organisiert. Zur Beurteilung der Versorgungsrealität ist
eine Datenanalyse und die Bewertung jedes Einzelfalles notwendig. Ein
Feedback der Ergebnisse muß für jeden Arzt und jede Klinik gegeben
sein. Die Kosten für dieses Informationsmanagement dürften bei zirka 0,3%
der Versorgungskosten der Patienten liegen.
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Introduction
Aim
The Ministry of Health is funding different approaches for the
documentation and support of regional health care of cancer
patients in eight regions in Germany. These approaches are
tested on the tracer diagnoses of lung, rectal, and breast
cancer. The conception of one of these studies and the initial
findings are shown here, using breast cancer in the region of
Munich as an example.
The aim of the study is to assess the medical care of all patients
with primary breast cancer and to evaluate the care carried out
according to the accepted standards of medical knowledge.
These requirements define this population-based observa-
tional study and with that a modern cancer registration which
verifies the health care from screening to therapy and outcome
[1–4]. The important indicators such as incidence, stage distri-
bution and relevant prognostic factors, surgical and conserva-
tive therapeutic measures, side effects, and finally survival
rates must be available [5–8]. The quality of life of the patients
is an important additional parameter [9, 10]. With this knowl-
edge the quality of health care can be verified and optimized,
if necessary. In this study, suitable methods for meaningful docu-
mentation, pathways of information exchange, and effective
quality management in oncology are developed and tested 
so that they can later be used in the routine care of cancer
patients.
Patient Care in Munich and the Surrounding Area
The realization of a cancer registry depends particularly on the
structure of the health care system. The German health care
system is decentralized with a separation of inpatient and out-
patient care. This complicates the work of the approximately
40 tumor centers which are mainly managed by the univer-
sities. The size of the region of a single comprehensive cancer
center varies from 1 to 5 million inhabitants. Munich and the
surrounding area (fig. 1) has a population of 2.4 million, of
which 9,800 per year will develop cancer, with a prevalence of
approximately 40,000 patients with former or current malig-
nant disease.
Patients and Methods
The study started on April 1, 1996. All patients who develop breast cancer
after this date and have their place or residence in Munich or the sur-
rounding area are included in the study. The recruitment phase is planned
for 2 years with a follow-up of 3–5 years. In the Munich region almost all
hospitals are involved. Physicians from both the in- and outpatient sector
as well as the patients themselves cooperate well in the documentation of
the complete course of the disease. Minimal information on screening, di-
agnostics, therapy, and follow-up as well as palliative care are registered on
documentation sheets. Verification of residence within the Munich region
is also documented. In addition, the original reports from the pathology,
surgery, radiotherapy and adjuvant chemotherapy or hormonal treatment
are availabe. The use of original reports minimizes the work effort for the
physicians and transfers it to the registry.
The initial report of each patient by means of documentation sheets and
original reports is carried out independently by the clinician involved in
the primary treatment. On the other hand, the cancer center receives the
pathology reports directly from the pathological institutes of the region.
For the update of the information, documents are regularly mailed to 
the practitioners involved in the posttreatment care. These forms already
contain the known treatment and follow-up data of the individual patient
so that the physicians only have to fill in the most recent results.
When the patient’s written consent is received from the hospital, the pa-
tients are asked 3 months following operation and then every 6 months
about their subjective opinion on quality of life as well as medical treat-
ment and personal care. The EORTC QLQ C30 (EORTC quality of life
questionnaire, core module 30) is part of this documentation of quality of
life [9, 10].
After completion of all these documents, sufficient information on the
actual health care can be achieved. Only some essential aspects are eval-
uated for this preliminary presentation, but the original reports offer addi-
tional detailed information for nested studies, which will be carried out
later regarding specific questions.
Fig. 1. The health care providers (in the ellipse)
and their contribution in the Munich region.
Qol = Quality of life.
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Results
Approximately 2,000 primary breast cancer cases per year 
are treated in the region of which 1,600 have their place of
residence within the defined region and which can therefore
be included in the study. From April 1, 1996 to June 30, 1997,
1,360 patients have been recruited in the region of Munich and
the surrounding area. This means approximately 85% of cases
have been recruited within the 1st year of the study and verify
a higher incidence for this region than originally expected 
(fig. 2). An exact calculation of incidence will only be possible
once the documentation is completed (including place of resi-
dence). In an other patient care study, a crude incidence of
125/100,000 women was reached also (information supplied by
Tumor Registry Aachen, unpublished data). Up to now the
only other incidence data in Germany have been available
from the Saarland with a crude incidence of 102.4/100,000
women and from a world standard of 57.0/100,000 for 1993.
Table 1 shows the distribution of pT stage according to the
detection modality of breast cancer. Correlation between
screening and stage distribution shows a shift to pT1 stage with
an assumed possibility of reduction in mortality. The stage shift
caused by regular screening could reduce mortality up to 35%
of the group without regular screening. The benefit of 35% can
be calculated from the stage-specific survival rates and the
stage shift by screening. The official screening programm in
Germany only involves palpation, but most of the tumors were
proven by mammography. Thus, whether the data ‘regular
screening’ includes mammography or not cannot be answered
reliably.
Tables 2 and 3 show the distribution of elementary clinical
data. This population-based registration gives an epidemiolog-
ical description of breast cancer and health care in the region
of Munich. The mean age rises by one year between pT 1 and
pT 3. There is a relatively high proportion of pT 1 with 54%
(table 2). In another patient care study in Germany (region of
Aachen) only 33% pT 1 could be ascertained (information
supplied by Tumor Registry Aachen, unpublished data). The
proportion of breast-conserving therapy (BCT) in the region
is 57%. Stage pT 1a is conspicuous with a larger proportion 
of multifocality/multicentricity and a larger proportion of
tumors with an intraductal component. This is also reflected
in the surgical therapy (table 3).
Initial results are also available for 3 other regions (Aachen,
Jena, Marburg) [11], and we expect to see considerable region-
al variability which also seems noticeable between the health
care providers. Tables 4 and 5 show variations of age, pT
stages, and proportion of BCT between the hospitals as ele-
mentary examples. In Germany breast cancer is treated by
gynecologists and surgeons. In the Munich region there are 
46 departments which operate on breast cancer patients. The
two groups shown are divided according to numbers of re-
cruited patients. Smaller hospitals have not only a larger pro-
portion of older patients (p < 0.001) but also more advanced
pT stages (not shown) (table 4). Despite the same distribution
of multifocality/multicentricity and intraductal components,
there is a significant difference of method of operation
(p < 0.001) between departments: A higher proportion of BCT
is carried out in the larger departments especially for the most
frequent stages pT 1 and pT 2 (table 5).
Figure 3 shows first results of quality of life examination
(EORTC QLQ C30) in different subgroups 3 months follow-
ing the operation. For comparison, the quality of life is shown
in respect to method of operation (BCT and mastectomy) 
as well as age under 50 years and over 70 years. There is no
difference in the quality of life between patients with BCT and
those with mastectomy. Differences of opinion are seen be-
tween the two age groups, the younger patients (< 50 years)
reporting a worse quality of life. The results for the patients
between 50 and 70 years (not shown in the graph) are about
the mean of the presented groups of age. The questionnaires
filled in by the patients are a valuable source of additional
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Fig. 2. Age-specific incidence rates for 1996 (for Munich). Mean age at
diagnosis: 60.8 years. Crude incidence 125/100,000 women, world standard
71.5/100,000. The incidence rate will be approximately 15% higher when
documentation is complete.
pT stage Regular self-examination  Regular screening  Regular screening                                 ______________________ ________________ ________________________________
yes no yes no discovered at discovered before
appointment appointment
n = 317 n = 244 n = 323 n = 246 n = 169 n = 143
pT 1 57 55 68 41 79 55
pT 2 32 33 27 40 18 39
pT 3 6 3 2 8 2 4
pT 4 4 8 2 11 1 3
a An effect of screening is verified by the shift to more favorable stages.
Table 1. Distribution of pT stages and 
screeninga
information. Over 80% of the patients addressed took the time
to answer the extensive questionnaire, which confirms they
want to be involved. The patient’s reports of actual health care
and tumor-specific health problems are an important contribu-
tion to the descriptions of health care reality (fig. 3).
Conclusions
Quality Management
To be able to make a statement about the quality of medical
care, it is necessary to have access to information about the
medical care provided [12]. This first step is almost achieved,
and a first selection of results can be presented. The actual
medical care must be evaluated according to recommended
standards e.g. approved guidelines for diagnostics, treatment
and follow-up of the respective disease [13–16]. Such an opti-
mized concept of health care must be compared with the reality
of the documented information. For years the Comprehensive
Cancer Center in Munich has provided standards in the form of
manuals for the most frequent tumors. Clinicians and general
practitioners meet regularly in tumor-specific project groups to
update these guidelines according to accepted scientific knowl-
edge and criteria of evidence-based-medicine (EBM) [17, 18].
In addition to these guidelines for medical procedures, this
patient care study has developed recommendations for the
content of all clinical reports to reduce the heterogeneity and
to make sure that all relevant information is documented. These
recommendations have been published and distributed within
the region [19–21].
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pT stage All Age group Age group Age group Mean Proportion Proportion Proportion
patients < 50 years 50–69 years > 70 years age N+ G 3 M 1
(21%) (52%) (27%) years (36%) (36%) (4.5%)
% % % % % % %
pTis 5 5 5 4 60.6 0 41 0
pT 1 54 51 59 45 59.7 25 26 2
pT 1a 5 4 6 3 58.3 15 27 0
pT 1b 12 10 13 10 60.6 14 18 2
pT 1c 37 37 40 32 59.6 29 29 2
pT 2 32 36 30 34 60.9 49 47 4
pT 3 4 4 4 5 61.9 72 58 13
pT 4 6 3 3 13 71.2 71 38 29
a n = 1,282 with data to all items.
Table 2. Clinical data
according to pT stagea
Table 3. Multifocality/multicentricity, intraductal component, and propor-
tion of BCT according to pT stagea
pT stage Multiple Intraductal component BCT
(n = 217) (n = 391) (n = 1,260)
proportion in % proportion in % proportion in %
pT 1a 31 66 50
pT 1b 18 31 76
pT 1c 14 35 69
pT 2 20 28 53
pT 3 21 17 6
pT 4 8 10 10
Total 17 31 57
a The intraductal component is presented as a general term and has still to
be evaluated as quantity, as described in the pathological reports.
Table 4. Distribution of different age groups according to department
magnitude
Age at diagnosis Department groups
according to number of treated (study-) patients________________________________________________
41 departments 5 departments
with < 50 patients (n = 559) with ‡ 50 patients (n = 801)
proportion in % proportion in %
< 50 years 36 64
50–69 years 35 65
> = 70 years 55 45
Total 41 59
Table 5. Proportion of BCT in the two department groups (see table 4)
pT stage Proportion of BCT, %_________________________________________________
Department group with Department group with
< 50 patients ‡ 50 patients
pTis 35 56
pT 1a 47 51
pT 1b 68 79
pT 1c 58 75
pT 2 40 62
pT 3 4 7
pT 4 10 11
Reality of Medical Care
To evaluate the reality of medical care, it is necessary to assess
each case individually using all documents. Firstly, the infor-
mation content of each report is evaluated: What does this
report convey? Secondly, the medical procedures are assessed
according to the given guidelines. The categories are: procedure
indicated/not indicated, carried out/not carried out, deviation
justifiable or substantiated/wrong. The data analysis delivers
the epidemiological results including quality of life and varia-
tions between the hospitals by evaluation of crucial parameters
of health care [2, 3, 7, 22–24]. Finally, the assessment of the
therapeutical procedures according to the above-mentioned
categories and the data analysis results of each health care
provider must be known.
Communication
Communication is an important part of an effective quality
management. This begins with good availability of standards
(lectures, postage of specific guidelines to selected health care
providers, manuals). This study provides information e.g. by
fax server: +49 89 7 40 05 67-XXXX (document number, 0004
= list of contents) and Internet at http://www.krebsinfo.de.
A feedback of the results and the long-term outcome includ-
ing individual cases must be made available to all practitio-
ners and clinical departments involved in the medical care.
Rare occurrences, casuistics, and internal statistics have to be
made available to the responsible physicians. Conspicuous-
ness or deviation from standard by a hospital or a practitioner
in comparision to the average results or to the guidelines are
to be pointed out and should motivate autonomous self-regu-
lation. Criteria for positive and negative deviations from guide-
lines are composed (by an independent panel of specialists)
with which the casuistics and hospital statistics are assessed
and interpreted. This information will be passed onto a hospi-
tal or practitioner as a kind of external quality review. The
success depends purely on the willingness to discuss such
discrepancies.
Cost
An important aspect of medical quality management are the
costs. A modern industry invests up to 10% of the balance ac-
count in its information management. Investment is also ne-
cessary in medicine for an effective ‘production of health’. In
Germany, 257 billion DM was spent on treatment in 1994, ap-
proximately 35 to 40 billion of that on cancer treatment. About
0.3% of that sum would be necessary for the support of an
adequate information management. In other words, 1 DM per
inhabitant per year. Therefore, it is not a question whether it is
affordable or not. It is obligatory as support for a high-quality,
appropriate health care. All health care providers should inte-
grate this account into their regular budgets.
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